ClinicalTrials.gg
CompletedNCT01506947Updated Jul 30, 2021Results posted

A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

A Phase 4 interventional study of Paricalcitol and Darbepoetin alfa in Moderate to Severe Secondary Hyperparathyroidism and Stage 5 Chronic Kidney Diseases, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-30.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing paricalcitol in Renal Insufficiency, Chronic — none open to participants now, none under way, none of them phase 3. paricalcitol · Renal Insufficiency, Chronic.

Enrollment
15th of 33
65 · median 60
Started
2012
with 1 other
Phase 4
10 of 33
none open now
Registered
29th of 33
by date
Lead sponsor
3 of 33
AbbVie (prior sponsor, Abbott)

Among the 33 studies testing paricalcitol in Renal Insufficiency, Chronic, this one is the 15th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 4, and was the 29th registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 33 studies testing paricalcitol in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

About paricalcitol

paricalcitol: first FDA approval 1998 (ZEMPLAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing paricalcitol in Renal Insufficiency, Chronic as a file.
02

Study summary

To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.

03

Conditions studied

  • Moderate to Severe Secondary Hyperparathyroidism
  • Stage 5 Chronic Kidney Diseases

Keywords

  • Hemodialysis
  • Chronic kidney disease
  • Secondary hyperparathyroidism,
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: A subject will only be included if all the following entry criteria are met:

  • Patients ≥ 18 years of age
  • Stage 5 chronic kidney disease (CKD) patients receiving hemodialysis and with moderate to severe secondary hyperparathyroidism (SHPT)
  • Patients with anemia due to renal insufficiency but who are iron replete:; Transferrin saturation (TSAT) > 20% and Ferritin levels > 200 ng/mL and requiring treatment with erythropoietin (EPO)
  • Patients with vitamin B levels > lower limit of normal (LLN) and folic acid levels > LLN
  • Patients treated only with intravenous calcitriol for at least 6 months
  • Patients with serum intact parathyroid hormone (iPTH) level > 500 pg/mL
  • Patients with calcium phosphate product (Ca × PO4) \< 65 mg²/dL²
  • Patients willing to sign "written informed consents" before participating in any the study related activity.
  • Patients with phosphorus levels \< 6.5 mg/dL and calcium levels \< 11.2 mg/dL

Exclusion Criteria:

A subject will be excluded from the study if he/she meets any of the following criteria:

  • Patients who have known and/or toxicity to vitamin D metabolites and/or to paricalcitol and/or to other product ingredients.
  • Patients who have participated in a clinical study within the last month.
  • Patients whose previous concomitant medication and laboratory data for 6 months prior to the baseline visit are not available.
  • Patients with known to selective Vitamin D receptor activators (VDRAs) according to the Summary of Product Characteristics (SmPC).
  • Pregnancy, breast-feeding or planning a pregnancy within next 6 months after enrollment. Sexually active female patients not accepting appropriate methods during the course of the study will also be excluded.
  • Hypertensive and diabetic patients who are not on an optimal and steady medication regimen for more than 30 days.
  • Patients with microcytic (mean corpuscular volume [MCV] \< 80 fL) and macrocytic (MCV > 100 fL) anemia at screening that may be caused by diseases such as for microcytic anemias - Iron Deficiency, Thalassemias, Anemia of Chronic Disease, Copper Deficiency, Zinc poisoning, Sideroblastic Anemia, macrocytic anemias -ethanol abuse, myelodysplastic syndromes, acute myeloid leukemias, reticulocytosis, drug induced anemia, liver disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Paricalcitol

    Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL. Participants may have also received routine darbepoetin alfa to treat anemia.

    Drug: Paricalcitol · Drug: Darbepoetin alfa

Interventions

  • Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula: \[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels.

    Also known as: ABT-358, Zemplar

  • Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.

06

What researchers measure

Primary outcomes

  1. Mean Erythropoietin Dose Per Visit

    The requirement of erythropoietin (EPO) treatment to maintain serum hemoglobin levels between 10 to 11.5 g/dL during the study was assessed by analysis of the dose of darbepoetin alfa used at baseline and during each month of the study. The mean EPO dosage per injection for each study month is reported.

    Time frame: Baseline and Months 1, 2, 3, 4, 5 and 6

Secondary outcomes

  1. Mean Scores of Short Form Health Survey 36 (SF-36) Questionnaire

    The Medical Outcome Study Short Form 36-Item Health Survey (SF-36) is a self-administered questionnaire that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains. The domains include physical (physical functioning, role limitations due to physical health (role-physical), general health perceptions and pain) and mental domains (energy/fatigue (vitality), social functioning, emotional well-being (mental health), and role limitations due to emotional problems (role emotional)). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    Time frame: Baseline and Month 6

  2. Mean Intact Parathyroid Hormone (iPTH) Level at Baseline and Month 6

    Time frame: Baseline and Month 6

  3. Mean Calcium Level at Baseline and Month 6

    Time frame: Baseline and Month 6

  4. Mean Phosphorus Level at Baseline and Month 6

    Time frame: Baseline and Month 6

  5. Mean Alkaline Phosphatase Level at Baseline and Month 6

    Time frame: Baseline and Month 6

  6. Vitamin B12 Levels

    Vitamin B12 levels were categorized according to the following laboratory reference ranges: Low: \< 200 pg/mL Normal: 200 - 950 pg/mL High: \> 950 pg/mL

    Time frame: Baseline and month 6

  7. Folic Acid Levels

    Folic acid levels were categorized according to the following laboratory reference ranges: Low: \< 4.6 ng/mL Normal: 4.6 - 18.7 ng/mL High: \> 18.7 ng/mL

    Time frame: Baseline and month 6

  8. Mean High Sensitivity C-reactive Protein (hsCRP) Level at Baseline and Month 6

    Time frame: Baseline and Month 6

  9. Mean Fibroblast Growth Factor-23 (FGF-23) Level at Baseline and Month 6

    Time frame: Baseline and Month 6

  10. Number of Participants With Adverse Events

    Serious adverse events were any adverse events meeting any of the following criteria: * An event that resulted in the death of a participant; * An event that, in the opinion of the investigator, would have resulted in immediate fatality if medical intervention had not been taken (life-threatening); * Resulted in an admission to the hospital for any length of time or prolonged hospital stay; * An anomaly detected at or after birth, or any anomaly that results in fetal loss; * An event that resulted in a condition that substantially interfered with the activities of daily living; * An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may have jeopardized the participant and may have required medical or surgical intervention to prevent any of the outcomes listed above. Adverse events were assessed by the investigator for possible relationship to study drug.

    Time frame: From the time of study drug administration until 4 weeks after the discontinuation of the study drug; up to 7 months.

07

Results

Posted May 15, 2017

Participant flow

This study was conducted at 7 centers in Turkey.

Participant flow — Overall Study
MilestoneParicalcitol
Started65
Completed49
Not completed16
Withdrew: Lost to follow-up7
Withdrew: Adverse event5
Withdrew: Death1
Withdrew: Did not meet eligibility criteria3

Outcome measures

PrimaryMean Erythropoietin Dose Per Visit

The requirement of erythropoietin (EPO) treatment to maintain serum hemoglobin levels between 10 to 11.5 g/dL during the study was assessed by analysis of the dose of darbepoetin alfa used at baseline and during each month of the study. The mean EPO dosage per injection for each study month is reported.

Time frame:
Baseline and Months 1, 2, 3, 4, 5 and 6
Reported as:
Mean · µg
Mean Erythropoietin Dose Per Visit
µgParicalcitol
Baseline35.8 ± 15.0
Month 122.2 ± 20.0
Month 222.7 ± 21.3
Month 34.7 ± 4.5
Month 47.2 ± 6.2
Month 517.3 ± 19.5
Month 621.8 ± 19.7
SecondaryMean Scores of Short Form Health Survey 36 (SF-36) Questionnaire

The Medical Outcome Study Short Form 36-Item Health Survey (SF-36) is a self-administered questionnaire that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains. The domains include physical (physical functioning, role limitations due to physical health (role-physical), general health perceptions and pain) and mental domains (energy/fatigue (vitality), social functioning, emotional well-being (mental health), and role limitations due to emotional problems (role emotional)). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

Time frame:
Baseline and Month 6
Reported as:
Mean · units on a scale
Mean Scores of Short Form Health Survey 36 (SF-36) Questionnaire
units on a scaleParicalcitol
Physical Function - Baseline51.7 ± 26.3
Physical Function - Month 651.5 ± 30.1
Role Physical - Baseline38.5 ± 45.2
Role Physical - Month 644.3 ± 46.5
Role Emotional - Baseline52.8 ± 46.0
Role Emotional - Month 654.2 ± 47.0
Vitality - Baseline47.4 ± 16.5
Vitality - Month 645.2 ± 17.0
Mental Health - Baseline54.5 ± 12.6
Mental Health - Month 652.7 ± 15.2
Social Functioning - Baseline59.6 ± 20.7
Social Functioning - Month 655.5 ± 26.3
Pain - Baseline61.3 ± 26.6
Pain - Month 660.5 ± 25.0
General Health - Baseline47.0 ± 16.9
General Health - Month 644.4 ± 22.3
SecondaryMean Intact Parathyroid Hormone (iPTH) Level at Baseline and Month 6
Time frame:
Baseline and Month 6
Reported as:
Mean · pg/mL
Mean Intact Parathyroid Hormone (iPTH) Level at Baseline and Month 6
pg/mLParicalcitol
Baseline918.0 ± 585.9
Month 6692.5 ± 413.4
SecondaryMean Calcium Level at Baseline and Month 6
Time frame:
Baseline and Month 6
Reported as:
Mean · mg/mL
Mean Calcium Level at Baseline and Month 6
mg/mLParicalcitol
Baseline8.81 ± 0.95
Month 69.29 ± 0.86
SecondaryMean Phosphorus Level at Baseline and Month 6
Time frame:
Baseline and Month 6
Reported as:
Mean · mg/mL
Mean Phosphorus Level at Baseline and Month 6
mg/mLParicalcitol
Baseline4.87 ± 1.11
Month 65.47 ± 1.22
SecondaryMean Alkaline Phosphatase Level at Baseline and Month 6
Time frame:
Baseline and Month 6
Reported as:
Mean · U/L
Mean Alkaline Phosphatase Level at Baseline and Month 6
U/LParicalcitol
Baseline225.7 ± 170.1
Month 6172.9 ± 147.6
SecondaryVitamin B12 Levels

Vitamin B12 levels were categorized according to the following laboratory reference ranges: Low: \< 200 pg/mL Normal: 200 - 950 pg/mL High: \> 950 pg/mL

Time frame:
Baseline and month 6
Reported as:
Count of participants · Participants
Vitamin B12 Levels
ParticipantsBaselineMonth 6
Low20
Normal1322
High3324
SecondaryFolic Acid Levels

Folic acid levels were categorized according to the following laboratory reference ranges: Low: \< 4.6 ng/mL Normal: 4.6 - 18.7 ng/mL High: \> 18.7 ng/mL

Time frame:
Baseline and month 6
Reported as:
Count of participants · Participants
Folic Acid Levels
ParticipantsBaselineMonth 6
Low14
Normal2525
High2217
SecondaryMean High Sensitivity C-reactive Protein (hsCRP) Level at Baseline and Month 6
Time frame:
Baseline and Month 6
Reported as:
Mean · mg/mL
Mean High Sensitivity C-reactive Protein (hsCRP) Level at Baseline and Month 6
mg/mLParicalcitol
Baseline11.8 ± 14.1
Month 614.4 ± 20.7
SecondaryMean Fibroblast Growth Factor-23 (FGF-23) Level at Baseline and Month 6
Time frame:
Baseline and Month 6
Reported as:
Mean · kRU/L
Mean Fibroblast Growth Factor-23 (FGF-23) Level at Baseline and Month 6
kRU/LParicalcitol
Baseline6267 ± 5967
Month 611340 ± 13450
SecondaryNumber of Participants With Adverse Events

Serious adverse events were any adverse events meeting any of the following criteria: * An event that resulted in the death of a participant; * An event that, in the opinion of the investigator, would have resulted in immediate fatality if medical intervention had not been taken (life-threatening); * Resulted in an admission to the hospital for any length of time or prolonged hospital stay; * An anomaly detected at or after birth, or any anomaly that results in fetal loss; * An event that resulted in a condition that substantially interfered with the activities of daily living; * An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may have jeopardized the participant and may have required medical or surgical intervention to prevent any of the outcomes listed above. Adverse events were assessed by the investigator for possible relationship to study drug.

Time frame:
From the time of study drug administration until 4 weeks after the discontinuation of the study drug; up to 7 months.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsParicalcitol
Non-serious adverse events9
Serious adverse events11
Treatment-related adverse events0
Fatal adverse events3

Adverse events

Collected over 6 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paricalcitol—11/65 (16.9%)1/65 (1.5%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventParicalcitol
DyspnoeaRespiratory, thoracic and mediastinal disorders4/65
AstheniaGeneral disorders2/65
Renal transplantSurgical and medical procedures2/65
PyrexiaGeneral disorders2/65
PalpitationsCardiac disorders2/65
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications2/65
NephrectomySurgical and medical procedures1/65
FatigueGeneral disorders1/65
Pleural effusionRespiratory, thoracic and mediastinal disorders1/65
AscitesGastrointestinal disorders1/65
Most frequent other events
Showing 10 of 15
Most frequent other events
EventParicalcitol
Arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications1/65
NasopharyngitisInfections and infestations1/65
Arteriovenous fistulaVascular disorders1/65
HeadacheNervous system disorders1/65
EpistaxisRespiratory, thoracic and mediastinal disorders1/65
HyperhidrosisSkin and subcutaneous tissue disorders1/65
VertigoEar and labyrinth disorders1/65
DizzinessNervous system disorders1/65
Chest painGeneral disorders1/65
DyspnoeaRespiratory, thoracic and mediastinal disorders1/65

Baseline characteristics

The per-protocol analysis set which included participants who completed the study according to the protocol. One patient was enrolled into the study under protocol version 1.0 and was not included in the per-protocol analysis set due to subsequent major changes to the protocol.

Age, Continuous
Age, Continuous(years)Paricalcitol
Mean49.6 ± 16.7
Sex: Female, Male
Sex: Female, Male(Participants)Paricalcitol
Female26
Male22
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Poordad F, Landis CS, Asatryan A, Jackson DF 3rd, Ng TI, Fu B, Lin CW, Yao B, Kort J. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int. 2016 Aug;36(8):1125-32. doi: 10.1111/liv.13067. Epub 2016 Feb 3. PubMed 26778412 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Apr 2016, 46 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

Of 117 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2011
First posted
Jan 10, 2012
StartActual
May 10, 2012
Primary completionActual
Apr 7, 2016
CompletionActual
Apr 7, 2016
Results first posted
May 15, 2017
Last update
Jul 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01506947
Responsible party
Sponsor
First posted
Jan 10, 2012
Start date
May 10, 2012
Primary completion
Apr 7, 2016
Completion
Apr 7, 2016
Results posted
May 15, 2017
Last update
Jul 30, 2021

Study contacts

Mahmut Gücük, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paricalcitol · Darbepoetin alfa

Start the discussion